633 related articles for article (PubMed ID: 26160155)
1. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
2. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
3. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
Remmers AE; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1999 Feb; 288(2):827-33. PubMed ID: 9918595
[TBL] [Abstract][Full Text] [Related]
4. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
5. Lack of evidence of kappa2-selective activation of G-proteins: kappa opioid receptor stimulation of [35S] GTPgammaS binding in guinea pig brain.
Childers SR; Xiao R; Vogt L; Sim LJ
Biochem Pharmacol; 1998 Jul; 56(1):113-20. PubMed ID: 9698095
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
[TBL] [Abstract][Full Text] [Related]
7. Dynorphin activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus.
Chen Z; Tang Y; Tao H; Li C; Zhang X; Liu Y
Neuropharmacology; 2015 Oct; 97():259-69. PubMed ID: 26056031
[TBL] [Abstract][Full Text] [Related]
8. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
9. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.
Xu M; Petraschka M; McLaughlin JP; Westenbroek RE; Caron MG; Lefkowitz RJ; Czyzyk TA; Pintar JE; Terman GW; Chavkin C
J Neurosci; 2004 May; 24(19):4576-84. PubMed ID: 15140929
[TBL] [Abstract][Full Text] [Related]
10. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.
Merg F; Filliol D; Usynin I; Bazov I; Bark N; Hurd YL; Yakovleva T; Kieffer BL; Bakalkin G
J Neurochem; 2006 Apr; 97(1):292-301. PubMed ID: 16515546
[TBL] [Abstract][Full Text] [Related]
11. Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
Nygard SK; Hourguettes NJ; Sobczak GG; Carlezon WA; Bruchas MR
J Neurosci; 2016 Sep; 36(38):9937-48. PubMed ID: 27656031
[TBL] [Abstract][Full Text] [Related]
12. Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.
Zhao Y; Joshi AA; Aldrich JV; Murray TF
Biomed Pharmacother; 2021 Nov; 143():112173. PubMed ID: 34536757
[TBL] [Abstract][Full Text] [Related]
13. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
Sirohi S; Aldrich JV; Walker BM
Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
[TBL] [Abstract][Full Text] [Related]
14. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
15. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
16. G(i1) and G(oA) differentially determine kinetic efficacies of agonists for kappa-opioid receptor.
Kohno M; Fukushima N; Yoshida A; Ueda H
FEBS Lett; 2000 May; 473(1):101-5. PubMed ID: 10802068
[TBL] [Abstract][Full Text] [Related]
17. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
18. Comparison of G-protein activation in the brain by mu-, delta-, and kappa-opioid receptor agonists in mu-opioid receptor knockout mice.
Park Y; Ma T; Tanaka S; Jang C; Loh HH; Ko KH; Ho IK
Brain Res Bull; 2000 Jul; 52(4):297-302. PubMed ID: 10856828
[TBL] [Abstract][Full Text] [Related]
19. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
20. Compartment-specific opioid receptor signaling is selectively modulated by different dynorphin peptides.
Kunselman JM; Gupta A; Gomes I; Devi LA; Puthenveedu MA
Elife; 2021 Apr; 10():. PubMed ID: 33908346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
